Compare MHO & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | LGND |
|---|---|---|
| Founded | 1976 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1995 | N/A |
| Metric | MHO | LGND |
|---|---|---|
| Price | $127.88 | $212.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $160.00 | ★ $245.00 |
| AVG Volume (30 Days) | ★ 209.0K | 162.5K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.74 | N/A |
| Revenue | ★ $4,417,781,000.00 | N/A |
| Revenue This Year | $0.66 | $0.74 |
| Revenue Next Year | $6.97 | $19.04 |
| P/E Ratio | ★ $8.70 | $76.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $100.22 | $93.58 |
| 52 Week High | $158.92 | $227.92 |
| Indicator | MHO | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 31.29 | 61.51 |
| Support Level | $124.48 | $179.55 |
| Resistance Level | $130.50 | N/A |
| Average True Range (ATR) | 4.45 | 10.01 |
| MACD | -1.84 | 2.42 |
| Stochastic Oscillator | 13.30 | 69.42 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.